Overview / Abstract: |
Oncology treatment teams are tasked with navigating through a steady increase in the number and complexity of molecular biomarkers that guide treatment decisions. FDA-approved companion tests have expanded testing options and provide uniformity of reporting, yet challenges in the clinical setting and the potential to negatively impact patient outcomes persist. As part of the continuum of care in oncology, there is an increasing demand for genomic testing to guide the course of treatment. |
Expiration |
Feb 13, 2019 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
AACME - 1.00 AMA PRA Category 1 Credit; ACPE - 1.00 hours (0.1 CEUs); ANCC - 1.1 contact hours; APRN - 1.0 contact hours pharmacology credit |
Accreditation |
AACME, ACPE, ANCC, APRN |
Presenters / Authors / Faculty |
Benjamin Levy, MD |
Activity Specialities / Related Topics |
Hematology, Oncology / Cancer / Radiation Therapy |
Sponsors / Supporters / Grant Providers |
This activity is supported by independent educational grants from AstraZeneca, Genentech, Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com |
Keywords / Search Terms |
Rockpointe oncology, hematology, biomarkers, RN, APN, NP, Registered Nurse, Advance Practice Nurse, Nurse Practitioner, Physician, Pharmacy, Pharmacist, Free CME, CME, CE, CME/CE Free CE CME |